KR20060118426A - 당뇨병성 신경병증성 통증 치료 및 수면 개선을 위한옥스카르바제핀의 용도 - Google Patents
당뇨병성 신경병증성 통증 치료 및 수면 개선을 위한옥스카르바제핀의 용도 Download PDFInfo
- Publication number
- KR20060118426A KR20060118426A KR1020067004340A KR20067004340A KR20060118426A KR 20060118426 A KR20060118426 A KR 20060118426A KR 1020067004340 A KR1020067004340 A KR 1020067004340A KR 20067004340 A KR20067004340 A KR 20067004340A KR 20060118426 A KR20060118426 A KR 20060118426A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- oxcarbazepine
- pain
- sleep
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960001816 oxcarbazepine Drugs 0.000 title claims abstract description 60
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 46
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
- 208000002193 Pain Diseases 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 24
- 230000002618 waking effect Effects 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical class C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0320637.2 | 2003-09-03 | ||
| GB0320637A GB0320637D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
| US53737804P | 2004-01-16 | 2004-01-16 | |
| US60/537,378 | 2004-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060118426A true KR20060118426A (ko) | 2006-11-23 |
Family
ID=34276821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067004340A Ceased KR20060118426A (ko) | 2003-09-03 | 2004-09-02 | 당뇨병성 신경병증성 통증 치료 및 수면 개선을 위한옥스카르바제핀의 용도 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060270658A1 (enExample) |
| EP (1) | EP1663247B1 (enExample) |
| JP (1) | JP2007513056A (enExample) |
| KR (1) | KR20060118426A (enExample) |
| AT (1) | ATE446759T1 (enExample) |
| AU (1) | AU2004268381B2 (enExample) |
| BR (1) | BRPI0414112A (enExample) |
| CA (1) | CA2537060A1 (enExample) |
| DE (1) | DE602004023861D1 (enExample) |
| IL (1) | IL173822A0 (enExample) |
| IS (1) | IS8373A (enExample) |
| MA (1) | MA28036A1 (enExample) |
| MX (1) | MXPA06002392A (enExample) |
| NO (1) | NO20061515L (enExample) |
| RU (1) | RU2369393C2 (enExample) |
| SG (1) | SG146631A1 (enExample) |
| TN (1) | TNSN06072A1 (enExample) |
| WO (1) | WO2005020968A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102486435B1 (ko) | 2022-04-25 | 2023-01-10 | 주식회사 제이비플랜트 | 산업용 냉동기기의 친환경 패널의 제조 방법 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| ES2396051T3 (es) * | 2006-04-26 | 2013-02-18 | Supernus Pharmaceuticals, Inc. | Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| GB0128674D0 (en) * | 2001-11-30 | 2002-01-23 | Boots Co Plc | Treatment of sleep disorders and the like |
| JP2006509735A (ja) * | 2002-10-17 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物 |
-
2004
- 2004-09-02 BR BRPI0414112-1A patent/BRPI0414112A/pt not_active IP Right Cessation
- 2004-09-02 CA CA002537060A patent/CA2537060A1/en not_active Abandoned
- 2004-09-02 DE DE602004023861T patent/DE602004023861D1/de not_active Expired - Lifetime
- 2004-09-02 RU RU2006110550/15A patent/RU2369393C2/ru not_active IP Right Cessation
- 2004-09-02 US US10/570,340 patent/US20060270658A1/en not_active Abandoned
- 2004-09-02 JP JP2006525105A patent/JP2007513056A/ja active Pending
- 2004-09-02 SG SG200806736-5A patent/SG146631A1/en unknown
- 2004-09-02 MX MXPA06002392A patent/MXPA06002392A/es not_active Application Discontinuation
- 2004-09-02 WO PCT/EP2004/009797 patent/WO2005020968A2/en not_active Ceased
- 2004-09-02 AT AT04764755T patent/ATE446759T1/de not_active IP Right Cessation
- 2004-09-02 AU AU2004268381A patent/AU2004268381B2/en not_active Ceased
- 2004-09-02 EP EP04764755A patent/EP1663247B1/en not_active Expired - Lifetime
- 2004-09-02 KR KR1020067004340A patent/KR20060118426A/ko not_active Ceased
-
2006
- 2006-02-20 IL IL173822A patent/IL173822A0/en unknown
- 2006-03-02 TN TNP2006000072A patent/TNSN06072A1/en unknown
- 2006-03-10 MA MA28869A patent/MA28036A1/fr unknown
- 2006-03-24 IS IS8373A patent/IS8373A/is unknown
- 2006-04-03 NO NO20061515A patent/NO20061515L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102486435B1 (ko) | 2022-04-25 | 2023-01-10 | 주식회사 제이비플랜트 | 산업용 냉동기기의 친환경 패널의 제조 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005020968A2 (en) | 2005-03-10 |
| RU2006110550A (ru) | 2007-12-20 |
| EP1663247B1 (en) | 2009-10-28 |
| TNSN06072A1 (en) | 2007-10-03 |
| JP2007513056A (ja) | 2007-05-24 |
| RU2369393C2 (ru) | 2009-10-10 |
| IL173822A0 (en) | 2006-07-05 |
| CA2537060A1 (en) | 2005-03-10 |
| ATE446759T1 (de) | 2009-11-15 |
| AU2004268381A1 (en) | 2005-03-10 |
| NO20061515L (no) | 2006-06-06 |
| BRPI0414112A (pt) | 2006-10-31 |
| WO2005020968A3 (en) | 2005-05-19 |
| SG146631A1 (en) | 2008-10-30 |
| US20060270658A1 (en) | 2006-11-30 |
| AU2004268381B2 (en) | 2009-06-18 |
| DE602004023861D1 (de) | 2009-12-10 |
| MA28036A1 (fr) | 2006-07-03 |
| EP1663247A2 (en) | 2006-06-07 |
| MXPA06002392A (es) | 2006-06-20 |
| IS8373A (is) | 2006-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| US5679685A (en) | Accelerated release composition containing bromocriptine | |
| US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
| AU2012281042B2 (en) | Combination ALS therapy | |
| CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
| AU2009304002B9 (en) | A medicinal product and treatment | |
| Todd et al. | Transdermal Nitroglycerin (Glyceryl Trinitrate: A Review of its Pharmacology and Therapeutic Use | |
| WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
| US10500170B2 (en) | Composition and method for treating neurological disease | |
| KR20070011276A (ko) | 쿠에티아핀 항정신병제를 사용한 정신병의 치료 | |
| HUP0203032A2 (hu) | Eplerenon gyorsan oldódó kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| KR20060118426A (ko) | 당뇨병성 신경병증성 통증 치료 및 수면 개선을 위한옥스카르바제핀의 용도 | |
| US11602510B2 (en) | Agent for use in the treatment of dyslipidemia | |
| PL200928B1 (pl) | Zastosowanie kwasu α-liponowego lub jego pochodnych do wytwarzania leku do zapobiegania albo leczenia migreny | |
| ZA200601502B (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and improvement of sleep | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| US11986458B1 (en) | Natural and synthetic andrographolides compounds for the treatment of skeletal muscular dystrophies | |
| RU2008108216A (ru) | Фармацевтические дозированные формы и составы, содержащие лекозотан | |
| EP4646204A1 (en) | Compound for treatment of erectile dysfunction | |
| US20020035157A1 (en) | Pharmaceutical compositions | |
| Frances et al. | Twenty‐four hour efficacy of two dose levels of a once daily sustained‐release diltiazem formulation in stable angina: a placebo‐controlled trial. The Dildurang Study Group. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060302 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20090520 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110423 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20110728 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110423 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |